Efficacy of clobetasol spray: Factors beyond patient compliance

References

• Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14(3):485–496.
   PubMedGoogle Scholar
• US Food and Drug Administration, Center for Drug Evaluation and Research. Clobex (clobetasol propionate) 0.05% spray. NDA 21-835 clinical pharamcology and biopharmaceutics review. 2005 July [cited 2010 April 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021835s000_ClinPharmR.pdf.
   Google Scholar
• Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque-type psoriasis. J Drugs Dermatol. 2006;5:357–360.
   PubMedGoogle Scholar
• Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque type psoriasis. Cutis. 2006;78:348–354.
   PubMed Web of Science ®Google Scholar
• Jacobsen C, Cornell RC, Savin RC. A comparison of clobetasol propionate 0.05% ointment and an optimized betamethasone dipropionate 0.05% ointment in the treatment of psoriasis. Cutis. 1986;37:213–214.
   Google Scholar
• Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185–192.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002;41:269–274.
   PubMed Web of Science ®Google Scholar
• Mraz S, Leonardi CL, Colon LE, Johnson LA. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J Dermatolog Treat. 2008;19:354–359.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer publications. J Clin Dermatol. 2009;10(6):397–406.
   Google Scholar
• Tanojo H, Huang X, Maibach HI. Foam for enhanced topical delivery: An overview. Dermatol Sinica. 2007;25:10–15.
   Google Scholar
• Wester RC, Maibach HI. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab Rev. 1983;14(2):169–205.
   Google Scholar
• Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology. 2005;210:157–168.
   PubMed Web of Science ®Google Scholar
• Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int J Pharm. 1991;76(1-2):1–8.
   Google Scholar
• Purdon CH, Haigh JM, Surber C. Foam drug delivery in dermatology: Beyond the scalp. Am J Drug Deliv. 2003;1:71–75.
   Google Scholar
• Bouwstra JA, Dubbelaar FE, Gooris GS, Ponec M. The lipid organisation in the skin barrier. Acta Derm Venereol Suppl. 2000;208:23–30.
   PubMedGoogle Scholar
• Williams ML, Elias PM. The extracellular matrix of stratum corneum: Role of lipids in normal and pathologic function. Crit Rev Ther Drug Carrier Syst. 1987;3(2):95–122.
   Google Scholar
• Barry BW. Drug delivery routes in the skin: A novel approach. Adv Drug Deliv Rev. 2002;S4(suppl 1):S31–S40.
   Google Scholar
• Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE J. 1975;21(5):985–996.
   Google Scholar
• Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603–618.
   PubMed Web of Science ®Google Scholar
• Trommer H, Neubert RHH. Overcoming the stratum corneum: The modulation of skin penetration. Skin Pharmacol Physiol. 2006;19:106–121.
   PubMed Web of Science ®Google Scholar
• Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: An overview. Skin Pharmacol Physiol. 2007;20:272–282.
   PubMed Web of Science ®Google Scholar
• Chowhan ZT, Pritchard R. Effect of surfactants on the percutaneous absorption of naproxen I: Comparisons of rabbit, rat, and human excised skin. J Pharm Sci. 1978;67:1272–1274.
   PubMed Web of Science ®Google Scholar
• Friend D, Catz P, Heller J, Reid J, Baker R. Simple alkyl esters as skin permeation enhancers. J Control Release. 1989;9:33–41.
   Web of Science ®Google Scholar
• Mohimi HR, Barry BW, Williams AC. Stratum corneum and barrier performance: A model lamellar structural approach. In: Bronaugh RL, Maibach HI, editors. Percutaneous absorption. New York, NY: Marcel Dekker; 2009. p. 515–554
   Google Scholar
• Smith EW, Maibach HI, editors. Percutaneous penetration enhancers. 2nd ed. Boca Raton, FL: CRC Press; 2005.
   Google Scholar
• Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121(1):63–67.
   Google Scholar
• Loncin M, Roth T, Bornhardt C. Influence of surface active agents on the drying rate of solids. In: Toei R, Mujumdar AS, editors. Drying 85'. New York: Hemisphere Publ Corp; 1985. p. 97–101.
   Google Scholar
• Clobex spray [package insert]. Dallas, TX: Galderma; 2007.
   Google Scholar